Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients

Author:

Luchsinger Larry L.1ORCID,Ransegnola Brett P.1,Jin Daniel K.1,Muecksch Frauke2,Weisblum Yiska2,Bao Weili3,George Parakkal Jovvian4,Rodriguez Marilis5,Tricoche Nancy4,Schmidt Fabian2,Gao Chengjie6,Jawahar Shabnam4,Pal Mouli3,Schnall Emily4,Zhang Huan6,Strauss Donna7,Yazdanbakhsh Karina3,Hillyer Christopher D.17,Bieniasz Paul D.28,Hatziioannou Theodora2

Affiliation:

1. Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

2. Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA

3. Laboratory of Complement Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

4. Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

5. Laboratory of Blood-Borne Parasites, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

6. Laboratory of Membrane Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

7. New York Blood Center Enterprises, New York, New York, USA

8. Howard Hughes Medical Institute, New York, New York, USA

Abstract

The development of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following infection or vaccination is likely to be critical for the development of sufficient population immunity to drive cessation of the coronavirus disease of 2019 (COVID-19) pandemic. A large number of serologic tests, platforms, and methodologies are being employed to determine seroprevalence in populations to select convalescent plasma samples for therapeutic trials and to guide policies about reopening.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3